AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

📰 Latest breakthroughs
🗺️ Disease Atlas · Cancer or benign tumor

cervical adenocarcinoma

An adenocarcinoma arising from the cervical epithelium. It accounts for approximately 15% of invasive cervical carcinomas. Increased numbers of sexual partners and human papillomavirus (HPV) infection are risk factors. Grossly, advanced cervical adenocarcinoma may present as an exophytic mass, an ulcerated lesion, or diffuse cervical enlargement. Microscopically, the majority of cervical adenocarcinomas are of the e…

🔔 Follow weekly
🧬1359genes / proteins with evidence
💊11drugs and clinical candidates
🧪12+recruiting trials worldwide
✅2phase 3
📈8phase 2
🧬

Understand cervical adenocarcinoma

Cancer · Cells that grow out of control
🎓 Learn more

What it is

An adenocarcinoma arising from the cervical epithelium. It accounts for approximately 15% of invasive cervical carcinomas. Increased numbers of sexual partners and human papillomavirus (HPV) infection are risk factors. Grossly, advanced cervical adenocarcinoma may present as an exophytic mass, an ulcerated lesion, or diffuse cervical enlargement. Microscopically, the majority of cervical adenocarcinomas are of the endocervical (mucinous) type.

From the Open Targets disease record ↗

🧬 Cancer: Cancer is a group of diseases in which some of the body's cells grow and divide without control, and can spread to other parts of the body.

❓ Why it happens

  • Changes (mutations) build up in the genes that tell a cell when to grow, divide and die.
  • Most of these changes happen during life: tobacco, too much sun, alcohol, some infections (such as HPV and hepatitis B and C), radiation, obesity and ageing all raise the risk.
  • Some people inherit a faulty gene that raises their risk, such as BRCA1 or BRCA2.

🫀 What it does to the body

  • Cancer cells form a lump (tumour) that can press on or invade nearby organs.
  • They can travel through the blood or lymph to start new tumours elsewhere (metastasis).
  • Blood cancers crowd out healthy blood cells in the bone marrow.

🧱 Why it is hard to cure

  • Every cancer is different, even between two people with the same type - and inside one tumour.
  • Cancer cells keep changing, so they can learn to resist a medicine that worked at first.
  • Cancer cells are the body's own cells, so killing them without harming healthy cells is hard.
  • Many cancers cause no symptoms until they have spread, and a new medicine often takes more than ten years to go from the lab to patients.

🚀 What research is trying now

  • Targeted medicines against the exact gene change in a tumour (for example EGFR, ALK or KRAS).
  • Immunotherapy that helps the immune system recognise cancer, including CAR-T cell therapy.
  • Personalised cancer vaccines built from each tumour's mutations, now in late trials.
  • Blood tests that look for tumour DNA to find cancer earlier, and AI to read scans and slides.

General information about cancer, reviewed by people; it does not describe any one person. Below: the evidence for cervical adenocarcinoma itself.

🤖

AI briefing

Where the science on cervical adenocarcinoma stands, from the evidence on this page

AI reads the targets, drugs, trials and papers below and writes where the science stands — every claim cited. It is shared with everyone who opens cervical adenocarcinoma.

🎯

Top targets

Genes and proteins ranked by Open Targets evidence (0-1)
STK11 serine/threonine kinase 11PROTACsmall molecule🧊 AlphaFold structure ↗ 0.49
KRAS KRas proto-oncogene, GTPasePROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.40
PTEN phosphatase and tensin homologPROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.40
TP53 tumor protein p53PROTACothersmall molecule🧊 AlphaFold structure ↗ 0.40
ERBB2 erb-b2 receptor tyrosine kinase 2PROTACantibodyothersmall molecule🧊 AlphaFold structure ↗ 0.39
PIK3CA phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alphaPROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.39
KMT2D lysine methyltransferase 2DPROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.38
FBXW7 F-box and WD repeat domain containing 7PROTACsmall molecule🧊 AlphaFold structure ↗ 0.38
MAML2 mastermind like transcriptional coactivator 2🧊 AlphaFold structure ↗ 0.37
CRTC1 CREB regulated transcription coactivator 1PROTACantibody🧊 AlphaFold structure ↗ 0.37
FGFR2 fibroblast growth factor receptor 2PROTACantibodyothersmall molecule🧊 AlphaFold structure ↗ 0.37
EP300 EP300 lysine acetyltransferasePROTACsmall molecule🧊 AlphaFold structure ↗ 0.36
ARID1A AT-rich interaction domain 1APROTAC🧊 AlphaFold structure ↗ 0.35
GATA3 GATA binding protein 3PROTAC🧊 AlphaFold structure ↗ 0.35
NOTCH1 notch receptor 1PROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.35

Green labels: what the target is known to be druggable by. The score combines genetics, somatic mutations, drugs, expression and literature.

💊

Drugs and candidates

Every medicine linked to cervical adenocarcinoma, by how far it has got
In phase 2 / 3 · 10
CemiplimabProgrammed cell death protein 1 inhibitorPhase 3
CisplatinPhase 3
CamrelizumabProgrammed cell death protein 1 antagonistPhase 2
CarboplatinPhase 2
IpilimumabCytotoxic T-lymphocyte protein 4 inhibitorPhase 2
NivolumabProgrammed cell death protein 1 inhibitorPhase 2
Show all 10
PembrolizumabProgrammed cell death protein 1 inhibitorPhase 2
PemetrexedThymidylate synthase inhibitor; Dihydrofolate reductase inhibitorPhase 2
Sacituzumab TirumotecanPhase 2
SerplulimabProgrammed cell death protein 1 antagonistPhase 2
🧪

Recruiting trials

Worldwide, open to new patients now
Preoperative Prediction of Lymph Node Metastasis in T1N0M0 Papillary Thyroid Carcinoma by Using Contrast-enha…NCT07357571 · n/a · 📍 GuangdongTrop2-targeted immunoPET Imaging of Solid TumorsNCT06851663 · Phase 2, Phase 3 · 📍 ShanghaiA Study of PF-08046054/SGN-PDL1V in Advanced Solid TumorsNCT05208762 · Phase 1 · 📍 BirminghamRegistry Platform Gastric/Esophageal Cancer (SAPHIR)NCT04290806 · n/a · 📍 Multiple LocationsAnti-Ly6E Exatecan ADC M7437 in Advanced Solid TumorsNCT07360314 · Phase 1 · 📍 New HavenA Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherap…NCT06023862 · Phase 2 · 📍 ClaytonGI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid TumorsNCT04977453 · Phase 1, Phase 2 · 📍 New YorkThe Clinical Outcomes and Prediction of Thermal Ablation for Low-risk Papillary Thyroid CarcinomaNCT06316895 · n/a · 📍 Beijing18F-T2 PET/CT Imaging for CAIX Positive Solid TumorsNCT07557225 · NA · 📍 BeijingMorning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tu…NCT07405086 · Phase 4 · 📍 PortlandStudy With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic TumorsNCT04777994 · Phase 1 · 📍 TucsonPhase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid TumorsNCT07006727 · Phase 1 · 📍 Iowa City Search more trials →
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy